Pages

Wednesday, August 24, 2011

美國安成(Anchen Pharmaceuticals) 賣給Par Pharma!!!

Par Pharma to buy generic drugmaker for $410 million Wed Aug 24, 2011 (Reuters) - Par Pharmaceutical Cos Inc (PRX.N) said it will buy privately held Anchen Pharmaceuticals for $410 million in cash to expand its generic drugs portfolio. Generic drugmakers, including Teva (TEVA.TA) (TEVA.O), Mylan (MYL.O) and Watson Pharmaceuticals (WPI.N), are scrambling for deals to add to their portfolios as they get ready to ride a wave of patent expirations that are about to hit the industry. Watson Pharma bought generic drug developer Specifar Pharmaceuticals SA in May while Teva sealed two deals during the same month to acquire specialty drugmaker Cephalon Inc (CEPH.O) and 57 percent of Taiyo Pharmaceutical. The largest U.S. maker of store-brand generic medicines Perrigo Co (PRGO.O) (PRGO.TA) added over 35 products to its portfolio with the acquisition of privately held Paddock Laboratories Inc in January this year. Par said the deal will almost double the portfolio of its generic new drug applications. "Anchen will expand our portfolio of high-value market products, including sustainable products with longer life cycles," said Paul Campanelli, president of the company's generics division, in a conference call. Par expects to complete the deal by the end of 2011. It sees the deal adding immediately to its 2011 earnings, excluding special items. The company plans to finance the transaction with cash on hand and a $350 million term loan. Irvine, California-based Anchen is a specialty pharmaceuticals firm focused on developing niche generic products and currently has five marketed products. Anchen expects to launch 8-10 niche generic products over the next two years, Par said in a statement. Par received a fairness opinion from J.P. Morgan in connection with the deal, while Anchen was advised by Jefferies & Co. This marks Par's second buy this year, after its $37.6 million cash deal with India-based Edict Pharmaceuticals -- another private maker of niche generic products. Par also has a branded drug division, Strativa Pharmaceuticals, which underwent a job cut recently in order to focus on two drugs -- a vitamin B12 nasal spray and an appetite loss drug. Par shares closed at $29.21 on Tuesday on the New York Stock Exchange.(Reporting by Esha Dey and Kavyanjali Kaushik in Bangalore; Editing by Maju Samuel ad Joyjeet Das)

中研院的澄清?!

多元使命的中央研究院(梁啟銘)2011 0824 為避免因資訊不完整而使讀者對中央研究院及院長之定位,產生以偏概全的印象,謹此澄清說明。中央研究院身為全國學術研究最高機關,首重基礎科學研究,傾全力追求學術卓越及創新。另為積極回應社會對學術界的期待,本院鼓勵同仁,在研究之餘,能落實各項研究成果,希望藉此帶動我國產業之創新及升級。此種特性,和英國皇家科學院等不從事實際研究的機構截然不同,不能類比。中央研究院院長身兼行政院首席科技顧問,經常要針對國家整體產業發展發言,故外界不應因為這些言論而混淆了本院的基本定位。此外,由於科技預算是政府對科、教、研的基礎投資,對於我國高等研究人才的培育及產業經濟的持續成長,影響至深,故本院屢次代表學術界,建請總統及行政院優予考量科技預算之編列。另為配合政府「生技起飛鑽石行動方案」,本院協助推動的「南港國家生技研究園區」,是利用本院近4000位生技研究人力,所研發具應用潛力的成果,就近、且迅速地轉移至園區內進行轉譯研究;園區內另有其他單位進駐,以利銜接基礎研究至動物及臨床試驗,往產業發展,加速台灣經濟轉型。研究園區顧名思義是以研究為主,不像其他科學園區,如新竹科學工業園區等,係以生產為主,因此主導單位亦有所不同。

謹記知識傳承之責 基於學術機關的自律,本院對於利益界定、利益揭露和利益衝突,已明確訂定處理原則與相關規範。全院從院長以至研究人員之兼職,皆依政府相關法令辦理,復經本院利益衝突規範專案小組與倫理委員會審議,所有由本院研究成果專利所取得的智慧財產權也都歸屬本院。研究人員兼任教授之職,亦皆秉持為國育才的理念。本院翁啟惠院長曾任職於美國Scripps研究院,於回國服務當時,即已放棄講座及約台幣3億元的研究經費,目前僅合作研究持續進行。翁院長在台大與清華的講座教授等職,全屬榮銜,既未領有報酬,亦未實際授課,僅參與指導學生從事研究。另,本院院長在外兼職需經總統府同意。學術研究作為一種志業,無法自閉於象牙塔中,而需與社會脈動相結合。本院經費由國家資助,故我們時刻謹記著學術研究承載著知識傳承及社會責任。 作者為中央研究院公共事務組主任

PEP02微脂體製劑授權成功 推智擎上興櫃

智擎生技 91登錄興櫃 2011/08/24 聯合晚報】由上櫃公司東洋 (4105)轉投資的智擎生技 (4162),將在91登錄興櫃,月底舉行登錄前法說會。智擎生技製藥公司成立於民國91年,目前實收資本額為7.41 億元。該公司發起人為上櫃公司東洋之轉投資事業專注於新藥開發。智擎公司以國際策略聯盟的方式進行新藥開發,為降低新藥開發的風險,並期望與合作夥伴達到雙贏的目的,以"No Research, Development Only (NRDO)"與"Networked Pharma (out-sourcing)"的模式,以成為「整合型新藥開發公司」,並成功建立台灣新藥開發產業價值鏈與成功的案例。目前主要開發藥物為PEP02 (Liposome irinotecan),係利用奈米科技開發喜樹鹼類抗癌藥物 (irinotecan)之微脂體製劑,定位在末期癌症病人治療,包括胰臟癌、大腸直腸癌、肺癌、胃癌與腦癌等。而今年7月中EP02經美國食品及藥物管理局FDA認定為治療胰臟癌的罕見疾病藥物的資格(orphan-Drug Designation)

Taiwan researchers discover protein that boosts cancer cell growth

2011/08/24  Taipei, Aug. 24 (CNA) An Academia Sinica research team has identified a protein -- called KLHL 20 -- that plays a key role in tumor progression, a discovery that could provide a new focus for future research into treating aggressive tumors. In a statement released by Taiwan's top academic institution on Wednesday, research team leader Chen Ruey-hwa said the KLHL 20 protein was induced by a protein called HIF-1, a key target of cancer researchers. HIF-1 regulates a large panel of genes that promote tumor cell survival in low oxygen conditions, induce cancer cell migration and contribute to resistance to chemotherapy and radiotherapy. Understanding how tumor cells control HIF-1 synthesis has long been an attractive cancer research topic and considered to be a major target for pharmaceutical intervention in cancer therapy, said Chen, deputy director of Academia Sinica's Institute of Biological Chemistry. The link to HIF-1 is key, Chen said, because of KLHL 20's ability to form a complex with proteins Cullin 3 and Roc 1 that can cause degradation of the protein PML, a well-known tumor suppressor protein. "PML itself inhibits HIF-1. Thus, the HIF-1-induced PML degradation successfully relieves the inhibitory effect of PML on HIF-1," Chen explained. Tumor cells, Chen added, exploit this mechanism to amplify HiF-1 production in the early phase of hypoxia or low oxygen conditions, thereby aiding tumor progression. The identification of KLHL 20's role in the mechanism could offer a new target for cancer drugs to break down HIF-1's proliferation and resistance to proteins or treatments, the Academia Sinica statement said. The study done by Chen's team has been published in the latest issue of leading cancer journal "Cancer Cell." The full article, called "A cullin3-KLHL20 ubiquitin ligase-dependent pathway targets PML to potentiate HIF-1 signaling and prostate cancer progression" can be found online at the Cancer Cell website at: http://www.sciencedirect.com/science/article/pii/S1535610811002637. (By Hsu Chih-wei and Sofia Wu) enditem/ls

植物幹細胞生物活性原料!!??

屏東農業生技園區的氣勢起來了!中國醫藥大學研發專利知識技術輸往南台灣 (中央社20110824)中國醫藥大學的研發專利知識技術輸往南台灣了!副校長吳永昌教授偕產學長吳金濱率產學合作團隊於22日南下屏東農業生物科技園區舉辦產業座談會,公開發表研發植物幹細胞生物活性原料、神經修補技術促進組織再生等生藥開發成果,並指導廠商辦理健康食品認証的撇步,與50餘家企業廠商交誼場面熱絡;屏農生技園區主任陳建斌稱許中國醫藥大學在中西醫藥與生物科技領域是取之不盡的寶庫,學術研發技術平台可以替產業界注入活水。『園區的氣勢起來了!』陳建斌主任開心的說,中國醫藥大學與農業生技園區結緣,扮演產學技術交流合作的「領頭羊」,對活絡在地產業的能量有積極的意義,況且,學校的產學技轉團隊全體動員的盛情感人,他同時感謝曾擔任生物科技園區推動委員會顧問的吳永昌副校長是積極促成的重要推手。位於屏東縣長治鄉的行政院農委會農業生物科技園區,於93年籌建開發面積約233公頃,陳建斌主任在簡報表示,園區規劃兼具研發、產銷、加工及轉運功能,以促進農業產業之轉型,加速形成農業科技產業聚落,現有進駐企業包括科技中草藥、水產生技、畜禽生技、生技美粧品、草本植物美妝品、植物類機能性食品、食用菇蕈類產品及草本保健食品業64家。高鐵通車後,台灣已是一日生活圈了;吳金濱產學長與廠商交流座談時表示,距離不是產學合作的問題,因為,在生醫科技研發能量充沛的中國醫藥大學與績優企業廠商開辦了『產學連結創新研發室』,以創新之模式,建立常態性、互動性的直接連結,透過遠距視訊、網際網路,提供即時的、全面性的資訊交流合作。副校長吳永昌教授表示,中國醫藥大學是榮獲2010年全國七大產學合作優質學校,近年來累積的智財申請與專利獲證高達209件之多,只要廠商有研發技術的需求,學校就會接招,尋找相關領域的教授和研發團隊做媒合技轉,共創多贏。對於台灣生醫材料技術,育成中心主任陳悅生教授在產業座談會介紹神經管修補技術的促進組織再生之生藥開發成果;在健康食品的開發方面,智財技轉中心主任林文川教授則以開發台灣金線連健康食品為例,從原物料的開發生產、品管、功效性與安全性評估到永續經營的核心價值,與業者分享實務經驗。此外,吳金濱產學長應廠商需求發表『植物幹細胞生物活性原料』的技術研發,讓與會業者興緻盎然。

化妝品很夯,如何萃取原料消除自由基、抗氧化?健康食品認証是否有其它替代原料?蘭菌否能提高台灣金線連指標成份的產量?植物培養槽的功能是否適用任何的植物?銀髮族的健康照護方向是開發器材仰或培訓人才?在屏東農業生物科技園區管理中心三樓國際會議廳舉辦的產業座談會場面熱絡,吸引50多家園區進駐企業與南部廠商派員參加,會場發言相當踴躍,主持座談的吳永昌副校長、吳金濱產學長都熱心解答並提供建言,同時彙整廠商在各專業領域面臨的困難和問題做追蹤輔導。中國醫藥大學產學團隊首度南下與屏東在地產業連結舉辦技術交流座談大受歡迎,屏農生技園區主任陳建斌期盼大學的人才智慧能加持強化產業競爭力,因此,他邀請中國醫大半年一次產學交流。對於屏農生技園區深耕在地產業帶動蓬勃發展的用心與誠摰邀約,副校長吳永昌教授深表肯定允諾大力促成,彼此建立更緊密的合作關係,共同為提昇農業科技產業技術盡一分心力。

藥師爆料???

藥師爆內幕 基層A健保藥費  2011/08/24(中央社)繼前衛生署長楊志良出書批評血汗醫院後,1位藥師也出書大爆診所A健保藥費、租牌藥局黑心推銷等內幕。他認為,癥結在於制度不良、稽核不實,及部分民眾「好騙難教」。這位先後任職醫學中心、開業診所及社區藥局,資歷超過10年的藥師告訴中央社記者,他的真心話不吐不快,但又顧慮身家性命,只好化名Drugs出版「白袍藥師的黑心履歷」,由出版社向楊志良、消費者文教基金會董事長蘇錦霞取得推薦。Drugs指出,中央健保局為簡化診所申報健保作業,實施「3日簡表申報」,即不論處方何種藥物,3天藥費一律總共新台幣66,診所醫師當然拚命用低於66元的廉價藥物,才能供得起先生娘血拚買名牌。Drugs分析,診所A藥費的常用花招是使用分裝藥,耳鼻喉或小兒科的感冒藥,健保多可給付原廠瓶裝的水劑,但診所常用不知名藥廠的大筒水藥,再分裝小瓶給病童服用;至於皮膚科診所大多以簡陋的塑膠盒盛裝藥膏,其實健保都可給付原廠條狀或罐狀、未開封的完整藥品。同時,設備簡陋的診所藥局,對兒童使用的磨粉藥,通常用坊間每台數百元的果汁機打碎充數,不僅分裝時會產生使用劑量不均的問題,馬虎且不重視清潔的陋習,更會讓小朋友吃到之前藥劑的殘餘,長期下來恐對身體產生不好的影響Drugs說,社區藥局、連鎖藥局穿白袍坐在櫃檯後面的人,不一定是藥師,Drugs說,正港藥師把牌照租給藥局,履見不鮮,就算是藥師執業,也時常傳出醫師開的是原廠A藥,藥房卻配同成份的廉價B藥,藥師賺價差,損害病人權益。他在書中披露,社區藥師大部分收入來自銷售保健食品、個人醫療用品,使用「奈米鈣」、「水解蛋白」等名詞來唬弄消費者,使消費者多花錢買下噱頭大於實效的成人奶粉、嬰幼兒食品、清潔用品等,甚至使寶寶接觸更多非天然的化學成份。Drugs認為,診所藥局在醫藥分業的基層,天高皇帝遠,稽核執法不實,亂象層出,台灣民眾衛教觀念不足,看不懂藥品標示,又執著「快快吃,馬上好」,且道聽塗說,也讓有心人士趁機大賺黑心錢,吃進不必要的藥品和來路不明的食品,增加肝腎負擔,無怪乎台灣的洗腎率名列世界前矛。

生達陳威仁兼任江蘇生達總經理!

生達化學:公告本公司董事會通過解除經理人競業禁止案 鉅亨網2011-08-24 生達化學:公告本公司董事會通過解除經理人競業禁止案  第二條 第21 1.董事會決議日:100/08/242.許可從事競業行為之經理人姓名及職稱:陳威仁-副總經理3.許可從事競業行為之項目:江蘇生達生技醫藥有限公司-總經理4.許可從事競業行為之期間:任職本公司經理人之職務期間5.決議情形(請依公司法第32條說明表決結果):全體出席董事同意通過6.所許可之競業行為如屬大陸地區事業之營業者,經理人姓名及職稱(非屬大陸地區事業之營業者,以下請輸〝不適用〞):陳威仁-副總經理7.所擔任該大陸地區事業之公司名稱及職務:江蘇生達生技醫藥有限公司-總經理8.所擔任該大陸地區事業地址:江蘇省泰州市藥城大道111029.所擔任該大陸地區事業營業項目:藥品研發及技術諮詢、技術服務10.對本公司財務業務之影響程度:11.經理人如有對該大陸地區事業從事投資者,其投資金額及持股比例:12.其他應敘明事項:

新配方玻尿酸化妝品市場開戰!

DR.WU「重量版」保濕聖品將於9月登場  (2011/8/24)自立晚報  連續四年締造超過百萬瓶熱銷奇蹟,台灣NO.1醫美品牌DR.WU即將於9月再度推出最令美妝達人引頸期盼的「重量版」保濕聖品─「玻尿酸保濕精華液101ML」以及「玻尿酸保濕化妝水500ML」、「海洋膠原保濕乳200ML」!採全新升級─「第三代智慧型多分子玻尿酸Hyalu-ComplexTM」配方,除了運用大、小分子與玻尿酸激發因子,全面啟動鎖水、補水、造水的「細胞水循環機制」,帶來更深層效的保濕潤澤效果外;同時添加有助活化纖維母細胞、刺激膠原蛋白增生的彈力蛋白及專利海洋膠原蛋白,讓肌膚不只水嫩飽滿,還細緻充滿彈力!此外,今年額外推出重量級熱銷商品-「玻尿酸保濕微導面膜15入」,且凡於活動期間9/7~10/4單筆消費滿1500元即可獲得只送不賣的「玻尿酸潤澤豐唇精華」、累積消費滿3800元就能入手全新上市的「氨基酸低敏洗卸二入組」! DR.WU第三代玻尿酸保濕配方,完美結合Sodium Hyaluronate大分子玻尿酸、Hyalo-Oligo®專利小分子玻尿酸與HyalufixTM GL玻尿酸激發因子,三管齊下全面啟動肌膚鎖水、補水、造水的「肌膚水循環機制」,全天候無間斷保濕,打造水嫩美肌!深度保濕還不夠,DR.WU專業團隊更要全面提升肌膚健康狀態!為徹底改善因乾燥而造成的各種肌膚問題,特別添加OCEAGEN®海洋膠原蛋白與Elastin Extract彈力蛋白,在玻尿酸進行三重潤澤修護的同時,刺激膠原蛋白增生,恢復肌膚原有彈力與緊緻;Active Yeast Extract活性酵母精華則同步加強新陳代謝,溫和排除老廢角質,讓肌膚自然透出健康白皙光采! DR.WU第三代智慧型多分子玻尿酸能防止細胞中的水份因氣候、環境影響而快速散失,緊緊抓鎖水分、深度補充滋潤,達到24小時持續保濕,且使用後10小時,肌膚含水量仍高達70%,超強保濕效果是一般保濕精華液的2倍!

Informal DOH survey finds many people store medicine incorrectly

2011/08/24 Taipei, Aug. 24 (CNA) An informal poll conducted by the Department of Health (DOH) has found that 40 percent of respondents did not store medicine properly or did not know how to properly dispose of unused drugs. The survey found that some respondents stored their medication in kitchens, bathrooms or bedrooms instead of cool and dry places as the DOH suggests, said Tsai Hsueh-yung, a section chief responsible for drug safety assessment under the DOG's Food and Drug Administration, on Wednesday. Tai said the most important principle in storing medicine is to keep it in a dark, dry drawer or cabinet away from heat, light and moisture. If medicine is exposed to humidity or heat -- the norm for bathrooms and kitchens -- it may lose its curative effect or even do more harm than good, Tai said. Getting rid of unused drugs and pills was another area in which people lacked basic knowledge, the survey found. Tai said that for most medications, burning them in an incinerator was the best option, but special drugs, including those prescribed to cancer patients, require more careful handling and should be returned to the hospital or clinic for proper disposal. Tai said it was important not to flush them down toilets or sinks because the drugs will dissolve and contaminate the water. The survey was conducted informally by the DOH in two stages and did not have a margin of error. The DOH said its purpose was simply to provide a rough idea of how people store and dispose of medicine in Taiwan.